ICER to propose IRA price methodology based on generic combos

ICER will evaluate a pair of GSK’s combination COPD products for which generic alternatives are available separately. The institute believes CMS may include the two products in the second cohort of drugs subject to price negotiations under the Inflation Reduction Act.

It’s the second year running that the Institute for Clinical and Economic Review has evaluated products in the context of the law’s drug pricing provisions. ...